New strategies and designs in pancreatic cancer research: Consensus guidelines report from a European expert panel

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 570-576

  Van Laethem, J L ^a   Verslype, C ^b   Iovanna, J L ^c   Michl, P ^d   Conroy, T ^e   Louvet, C ^f   Hamme, P ^g   Mitry, E ^h   Ducreux, M ⁱ   Maraculla, T ^j   Uhl, W ^k   Van Tienhoven, G ^l   Bachet, J B ^m   Chal, R Maré ^a   Hendlisz, A ⁿ   Bali, M ^a   Demetter, P ^a   Ulrich, F ^o   Aust, D ^p   Luttges, J ^q   Peeters, M ^r   Mauer, M ^s   Roth, A ^t   Neoptolemos, J P ^u   Lutz, M ^q   more..

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSERM   (France)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITÉ DE LORRAINE   (France)

^f INSTITUT MUTUALISTE MONTSOURIS   (France)

^g BEAUJON HOSPITAL   (France)

^h INSTITUT CURIE   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k ST JOSEF HOSPITAL   (Germany)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

^m ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁿ JULES BORDET INSTITUTE   (Belgium)

^o UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^p UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^q Caritasklinik St Theresia   (Germany)

^r ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^s EORTC DATA CENTER   (Belgium)

^t GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^u UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

Chemoradiation; FOLFIRINOX; Pancreatic cancer; Preclinical; Research strategy

Indexed keywords

ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER MODEL; CANCER RESEARCH; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; HIGH THROUGHPUT SCREENING; HUMAN; NAUSEA; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESEARCH PRIORITY; REVIEW; TISSUE PRESERVATION;

EID: 84857606982     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr351     Document Type: Review

References (45)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Coleman MP, Gatta G, Verdecchia A et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14 (Suppl 5): V128-V149.
3. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21: 195-200.
4. Neoptolemos JP, Stocken DD, Friess H et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
5. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2008; 297: 267-277.
6. Ueno H, Kosuge T, Matsuyama Y et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-915.
7. Kaiser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120(8): 899-903.
8. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782.
9. Smeenk HG, van Eijck CH, Hop WC et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007; 246: 734-740.
10. Van Laethem JL, Hammel P, Mornex F et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010; 28: 4450-4456.
11. Huguet F, Girard N, Guerche CS et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27: 2269-2277.
12. Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and phase III studies. J Clin Oncol 2007; 25: 326-331.
13. Yip D, Karapetis C, Strickland A et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006; 3: CD002093. doi: 10.1002/14651858.CD002093.pub2.
14. Sultana A, Smith CT, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615.
15. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952.
16. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
17. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364(19): 1817-1825.
18. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321(5897): 1801-1806.
19. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006; 13: 286-295.
20. Omura N, Goggins M. Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol 2009; 2: 310-326.
21. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324(5933): 1457-1461.
22. Beatty GL, Chiorean EG. Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331(6024): 1612-1616.
23. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
24. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009; 85: 217-221.
25. Hingorani SR, Petricoin EF, Maitra A et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
26. Hingorani SR, Wang L, Multani AS et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
27. Guerra C, Schuhmacher AJ, Can{ogonek} amero M et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007; 11: 291-302.
28. Michalski CW, Erkan M, Sauliunaite D et al. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 2008; 99: 760-767.
29. Tersmette AC, Petersen GM, Offerhaus GJA et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7: 738-744.
30. Pitt KE, Campbell LD, Skubitz APN et al. International Society for Biological and Environmental Repositories. 2008 Best practices for repositories: collection, storage, retrieval and distribution of biological materials for research. Cell Preserv Technol 2008; 6: 3-58.
31. Tofts PS, Brix G, Buckley D et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. JMRI 1999; 10: 223-232.
32. Bali MA, Metens T, Denolin V et al. Pancreatic perfusion: non-invasive quantitative assessment with dynamic contrast-enhanced MR imaging without and with secretin stimulation in healthy volunteers. Initial results. Radiology 2008; 247: 115-121.
33. Akisik MF, Sandrasegaran K, Bu G et al. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antioangiogenic therapy. Radiology 2010; 256: 441-449.
34. Neoptolemos JP, Stocken DD, Bassi C et al. European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081.
35. Oberstein PE, Saif MW. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium." San Francisco, CA, USA. January 20-22, 2011. JOP 2011; 12: 96-100.
36. Van Geenen RC, Keyzer-Dekker CM, van Tienhoven G et al. Pain management of patients with unresectable peripancreatic carcinoma. World J Surg 2002; 26: 715-720.
37. Morak MJ, Richel DJ, van Eijck CH et al. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother Oncol 2011; 98: 261-264.
38. Gillen S, Schuster T, Meyer Zum Bü schenfelde C et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267. doi:10.1371/journal.pmed.1000267.
39. Van Tienhoven G, Gouma DJ, Richel DJ. Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Ther Adv Med Oncol 2011; 3: 27-33.
40. Pelzer A, Kubica K, Stieler J et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26 (Suppl): (Abstr 4508).
41. da Cunha Santos G, Dhani N, Tu D et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010; 116: 5599-5607.
42. Bachet JB, Maré chal R, Van Laethem JL. Treatment of pancreatic cancer: what can we really predict today? Cancers 2011; 3: 675-699.
43. Farrell JJ, Elsaleh H, Garcia M et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136(1): 187-195.
44. Maré chal R, Mackey JR, Lai R et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009; 15: 2913-2919.
45. Maré chal R, Mackey JR, Lai R et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010; 116: 5200-5206.